Stay updated on Oral Upadacitinib in Atopic Dermatitis Clinical Trial

Sign up to get notified when there's something new on the Oral Upadacitinib in Atopic Dermatitis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Oral Upadacitinib in Atopic Dermatitis Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The study record appears unchanged.
    Difference
    0.1%
    Check dated 2026-11-14T13:46:00.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The page now presents AbbVie’s study of upadacitinib for moderate-to-severe atopic dermatitis in Brazil, including its design, eligibility criteria, and outcome measures. The record also provides data-sharing information and indicates the study was withdrawn with actual enrollment of zero.
    Difference
    49%
    Check dated 2026-11-07T13:24:05.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0 while the study page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T14:13:34.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces updates and FAQs about its terminology transition from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-24T16:32:40.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-17T16:27:30.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The revision identifier in the site footer changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-10T16:20:01.000Z thumbnail image

Stay in the know with updates to Oral Upadacitinib in Atopic Dermatitis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Oral Upadacitinib in Atopic Dermatitis Clinical Trial page.